| Name | Title | Contact Details |
|---|
New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The FidoCure® team is committed to introducing the therapies that have been successfully used to treat humans with cancer into the world of veterinary medicine. Currently, cancer care for dogs lags behind human cancer care by about 20 years. Our goal is to improve the outcome for canine cancer patients. We are the first and only company to offer the information needed to work with your veterinarian on targeted medicines for dogs with cancer.
Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the recent development of the Feldan Shuttle, this approach is starting to show its promises. Feldan`s mission is to develop regenerative medicine therapeutic applications based on Feldan`s proprietary technology.
harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").